Zhengye Biotechnology Holding LTD F-1 registration statements

Zhengye Biotechnology Holding Limited, a Cayman Islands-based veterinary vaccine company with operations primarily in China, is seeking to raise $7.5 million through an initial public offering on the Nasdaq Capital Market, facing potential regulatory hurdles and operational risks.

Zhengye Biotechnology Holding Limited aims to raise capital for acquisitions and R&D through an initial public offering of 1.5 million ordinary shares, with a potential additional 225,000 shares via an underwriter option.

Zhengye Biotechnology Holding Limited is pursuing an initial public offering of 1.25 million ordinary shares, aiming for a Nasdaq listing and proceeds for acquisitions and R&D.

Zhengye Biotechnology Holding Limited files an amendment to its F-1 registration statement for an initial public offering, aiming to list its ordinary shares on the Nasdaq Capital Market.